ALPHEE study [Kowey PR et al. Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. 2011;124:2649-60] compared the efficacy and safety of celivarone, a new antiarrhythmic drug with the age old amiodarone. This was a randomized double blind placebo controlled parallel group study of around five hundred patients with left ventricular dysfunction and at least one appropriate implantable cardioverter-defibrillator (ICD) intervention in the previous month for a ventricular tachyarrhythmia. They had evaluated celivarone in doses of 50, 100 and 300 mg and found that none of the comparisons with placebo were statistically significant. But it had an acceptable safety profile. The authors finally concluded that celivarone was not effective for the prevention of ICD intervention or sudden death.